{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:27:21Z","timestamp":1780338441186,"version":"3.54.1"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Over a century ago, atropine has been tested to arrest myopia progression with good results. In recent years, many randomized clinical trials have tested different concentrations against placebo. Three recent such studies with low\u2010dose atropine showed that it was less effective than previous studies, even the last one showing no difference in myopia progression between the treated and control group. Previous randomized studies had been performed in Asian populations, and these last three were extended to Western Caucasian populations, based on the initial observation that differences in iris pigmentation could be a factor for a difference in effectiveness. We have noticed that the three last studies in the West have used the same patented formulation, while previous studies have preferred compounded low\u2010dose atropine. Here we review how the power of hydrogen (pH) and preservatives could account for differences in drug penetration to the eye, possibly explaining the differences between studies.<\/jats:p>","DOI":"10.1111\/aos.16604","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T09:43:55Z","timestamp":1703238235000},"page":"364-366","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preservatives and <scp>pH<\/scp> in low\u2010dose atropine formulations for clinical trials"],"prefix":"10.1111","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3719-2195","authenticated-orcid":false,"given":"Rafael","family":"Iribarren","sequence":"first","affiliation":[{"name":"Drs. Iribarren Eye Consultants  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Cunha","sequence":"additional","affiliation":[{"name":"Oftalmocenter Santa Rosa Cuiab\u00e1  Cuiab\u00e1 Mato Grosso Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5006-7420","authenticated-orcid":false,"given":"Hakan","family":"Kaymak","sequence":"additional","affiliation":[{"name":"Internationale Innovative Ophthalmochirurgie GbR  Duesseldorf Germany"},{"name":"Institute for Experimental Ophthalmology Saarland University  Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-2391","authenticated-orcid":false,"given":"Andrzej","family":"Grzybowski","sequence":"additional","affiliation":[{"name":"Institute for Research in Ophthalmology Foundation for Ophthalmology Development  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040588"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4274572"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.07.004"},{"key":"e_1_2_2_5_1","first-page":"139","article-title":"On the atropine treatment of acquired and progressive myopia","volume":"2","author":"Derby H.","year":"1874","journal-title":"Transactions of the American Ophthalmological Society"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol\u20102019\u2010315440"},{"key":"e_1_2_2_7_1","first-page":"4145","article-title":"Effect of Benzalkonium chloride in corneal permeation of low dose atropine","volume":"64","author":"Gil\u2010Cazorla R.I.A.","year":"2023","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.1091"},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273972.2017.1421675"},{"key":"e_1_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.016"},{"key":"e_1_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384\u2010021\u201000822\u2010y"},{"key":"e_1_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4835(80)90114-1"},{"key":"e_1_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1457_18"},{"key":"e_1_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.3030460905"},{"key":"e_1_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1339_22"},{"key":"e_1_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14148"},{"key":"e_1_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.004"},{"key":"e_1_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15761"},{"key":"e_1_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12052"},{"key":"e_1_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.12688\/hrbopenres.12914.1"},{"key":"e_1_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2022-322808"},{"key":"e_1_2_2_22_1","volume-title":"Atropine pharmaceutical compositions","author":"Puri N.A.P.","year":"2018"},{"key":"e_1_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.2855"},{"key":"e_1_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000990"},{"key":"e_1_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.5.2"},{"key":"e_1_2_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.01.026"},{"key":"e_1_2_2_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/opo.13192"},{"key":"e_1_2_2_28_1","volume-title":"Atropine\u2010containing aqueous composition","author":"Tan D.","year":"2017"},{"key":"e_1_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.3076"},{"key":"e_1_2_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111092"},{"key":"e_1_2_2_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.3820"},{"key":"e_1_2_2_32_1","volume-title":"Report of the joint World Health Organization\u2013Brien Holden vision institute global scientific meeting on myopia","author":"WHO","year":"2016"},{"key":"e_1_2_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.011"},{"key":"e_1_2_2_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.2097"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.16604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T05:01:20Z","timestamp":1712638880000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.16604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/aos.16604"],"URL":"https:\/\/doi.org\/10.1111\/aos.16604","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"2023-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}